Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Panic Disorder
Interventions: suvorexant, placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Fresno, California

Conditions: Anxiety Disorders
Interventions: Threat of shock; Device
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 921 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Cognitive Remediation, Computer Games; Behavioral
Lead sponsor: Wesleyan University; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Hartford, Connecticut • Middletown, Connecticut

Conditions: Body Composition, Executive Functioning, Temperament
Interventions: Observation; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 4 Months to 24 Months
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Cytal Wound Matrix 1-Layer, Standard of Care (SOC); Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions: Radiation Therapy, Pembrolizumab, Nab-paclitaxel, Paclitaxel, Carboplatin, Gemcitabine, Biopsy, Computed Tomography, Bone Scan, Biospecimen Collection, Medical Chart Review; Radiation · Biological · Drug + 2 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Spinal Cord Injuries, Neuropathic Pain
Interventions: Cognitive Multisensory Therapy, Usual Care, Clinical Assessment, Magnetic Resonance Imaging (MRI), OPTIONAL: blood draw; Behavioral · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neurofibromatosis Type 1, Precancerous Condition
Interventions: fludeoxyglucose F 18, gadopentetate dimeglumine; Radiation
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 25 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Burixafor Hydrobromide, Docetaxel, G-CSF; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
Interventions: Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin; Drug
Lead sponsor: Columbia University; Other
Eligibility: Up to 30 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use, Alcohol Use Disorder
Interventions: repetitive transcranial magnetic stimulation (rTMS) for AUD, repetitive transcranial magnetic stimulation (rTMS) for OUD; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Insomnia
Interventions: Sleep Education Program, Mind-Body Bridging Program, Mindfulness Meditation Program; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
Interventions: Clopidogrel, Ticagrelor; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5,276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 26
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 20 more

Conditions: Cystic Fibrosis
Interventions: Placebo, Tobi Podhaler; Drug · Device
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 9 more

Conditions: Stress, Psychological
Interventions: Web-based Stress Management Program (WSM), Group Support (WSMg1), Clinical Expert Support (WSMg2); Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Omega-3 Deficiency, DHA and EPA Blood Levels, Cardiovascular Health, Cognitive Health
Interventions: Omega Active Supplement; Dietary Supplement
Lead sponsor: Revive Active; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Sickle Cell Disease, Depression, Anxiety
Interventions: Computerized cognitive behavioral therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Crohn's Disease
Interventions: 4-Aminosalicylic acid, PASER placebo granules; Drug
Lead sponsor: Jacobus Pharmaceutical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Charlotte, North Carolina

Conditions: Relapsed or Refractory Follicular Lymphoma
Interventions: Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 17
States / cities: Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more

Conditions: Myocardial Infarction, Heart Failure, Heart Valve Diseases, Cardiac Event, Angina Pectoris, Coronary Artery Disease
Interventions: HYCR, CBCR; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Nicotine Dependence
Interventions: Varenicline, Bupropion, Nicotine patches, Placebo varenicline, Placebo bupropion, Placebo patch; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Parkinson Disease
Interventions: Varenicline, Sugar pill; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Mental State, Reported as Depression, Anxiety or Stress
Interventions: Give a massage; Behavioral
Lead sponsor: Parker Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rotator Cuff Tear
Interventions: Platelet Rich Plasma (PRP), Corticosteroid; Biological · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

The Role of Orexin in Human Panic Disorder

Expectation of Unpleasant Events in Anxiety Disorders

Comparing Cognitive Remediation Approaches for Schizophrenia

Early Genetic and Environmental Influences on Eating - The Baylor Infant Twins Study

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Identifying Body Awareness-related Brain Network Changes During Cognitive Multisensory Rehabilitation for Reduced Neuropathic Pain in People With Spinal Cord Injury

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

rTMS as Add on Treatment for Substance Use Disorders

Sleep Management in Cancer Survivors

Tailored Antiplatelet Therapy Following PCI

Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

Stress Free Now in a Corporate Call Center

A Clinical Trial to Evaluate the Effects of an Omega-3-containing Supplement on DHA and EPA Levels in the Blood

Cognitive Behavioral Therapy and Real-time Self-management Intervention for SCD Via Mobile Applications

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

The Improving ATTENDance to Cardiac Rehabilitation Trial

Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation

Varenicline for Gait and Balance Impairment in Parkinson Disease

The Impact of Giving a Massage

Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears